SARS CoV 2 News and Research

RSS

Scientists urge health agencies to invest in COVID-19 vaccine development to prevent next pandemic

As new COVID-19 variants begin to throw vaccine efficacy in question, two leading scientists are calling for health agencies to invest in the development of vaccines that would be broadly effective against many different variants and strains of potential pandemic viruses.

10 Feb 2021

Relaxed control measures are driving wintertime outbreaks of COVID-19

Wintertime outbreaks of COVID-19 have been largely driven by whether people adhere to control measures such as mask wearing and social distancing, according to a study published Feb. 8 in Nature Communications by Princeton University researchers.

10 Feb 2021

Fred Hutch researchers predict a 4th wave of SARS-CoV-2

Recently, researchers from France and the USA analyzed the complexities of vaccine implementation during the 3rd wave of SARS-CoV-2 infections and potentially future waves, using a mathematical model calibrated to data from King County, Washington.

9 Feb 2021

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants.

9 Feb 2021

SARS-CoV-2 B.1.1.7 may soon become the dominant variant in US

A team of scientists from the United States has recently explored the prevalence and transmission dynamics of the B.1.1.7 variant (UK variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States. The study reveals that because of 35-45% increased transmissibility, B.1.1.7 may soon become the US's dominant variant. The study is currently available on the medRxiv* preprint server.

9 Feb 2021

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Researchers at NYU Grossman School of Medicine in New York have conducted a study demonstrating the effectiveness of the Pfizer-BioNtech BNT162b2 vaccine against recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Feb 2021

Model estimates COVID-19 cases in the U.S. to be three times greater than reported

World health experts have long suspected that the incidence of COVID-19 has been higher than reported.

9 Feb 2021

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers in China have developed three SARS-CoV-2 nanoparticle vaccines, containing receptor-binding domain (RBD) trimer, S1 trimer, and ectodomain (ECD) trimer, respectively. To do this, they have used Ferritin nanoparticle self-assembly technology.

9 Feb 2021

COVID-19 vaccination associated with 3- to 5-fold reduction in viral load

Researchers in Israel report a reduction in viral load in vaccinated individuals.

9 Feb 2021

Smell and taste loss symptoms associated with robust SARS-CoV-2 antibody response in new study

Researchers in Italy report a correlation between the loss of smell and taste and an observed persistence or rise in antibody levels at five months after infection.

9 Feb 2021

Inhibition of protein glycosylation successfully prevents SARS-CoV-2 infection in vitro

A new study provides direct evidence that the oligosaccharides attached to the viral surface spike protein are essential for viral infection, offering new approaches to preventive and therapeutic drugs.

9 Feb 2021

Subgenomic RNAs could help identify asymptomatic SARS-CoV-2 infection

Researchers report the association of subgenomic RNA (sgRNA) production, the structural differences between sgRNA variants, and clinical severity in 81 clinical specimens obtained from both asymptomatic and symptomatic individuals with SARS-CoV-2 infection.

9 Feb 2021

Emergence and transmission of UK SARS-CoV-2 variant in the US

Researchers describe the impending rise to dominance of the B.1.1.7 (UK) variant in the US. Understanding this development will help to shape preventive action to reduce the infection and mortality rates.

9 Feb 2021

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

A new study describes the first case of anti-SARS-CoV-2 antibodies detected in the cord blood of an infant born to a mother immunized with the first dose of an mRNA COVID-19 vaccine three weeks earlier.

9 Feb 2021

A precursor to remdesivir shows therapeutic potential for COVID-19

A new study points to the potential to use the remdesivir precursor, GS-441524, as a treatment choice for COVID-19.

9 Feb 2021

New machine-learning algorithm estimates number of COVID-19 cases in the U.S.

World health experts have long suspected that the incidence of COVID-19 has been higher than reported. Now, a machine-learning algorithm developed at UT Southwestern estimates that the number of COVID-19 cases in the U.S. since the pandemic began is nearly three times that of confirmed cases.

8 Feb 2021

New U.K. SARS-CoV-2 variant may cause more severe illness, study finds

Researchers at the London School of Hygiene and Tropical Medicine revealed that the VOC 202012/01 variant is not only fast-spreading and easily transmissible but also may cause more severe illness.

8 Feb 2021

Type of aspirating system significantly affects SARS-CoV-2 incidence among dental specialists

High-volume aspirators are recommended in dental clinics during the COVID-19 pandemic, but the study "SARS-CoV-2 Seropositivity Among Dental Staff and the Role of Aspirating Systems" published in the JDR Clinical & Translational Research (JDR CTR), shows that the type of aspirating system significantly affects the incidence of SARS-CoV-2 infection among dental specialists.

8 Feb 2021

One-dose SARS-CoV-2 vaccine policy may lead to antigenic evolution, study finds

In a new study, published on the pre-print server medRxiv, an international team of researchers found that a one-dose policy may increase the potential for antigenic evolution. The study revealed that focusing on one dose may decrease infections in the short term, but longer-term outcomes rely on this immune strength.

8 Feb 2021

Pfizer-BioNTech COVID-19 vaccine immune response in the elderly

In a recent medRxiv preprint publication, the team led by Professor Ravindra K. Gupta has assessed the real-world immune responses following the vaccination against the SARS-CoV-2. The team measured 1) IFN-gamma (interferon-gamma) T cell responses, 2) both total IgG Spike/ IgG Spike RBD (receptor binding domain) and 3) neutralizing antibody responses to Spike in sera.

8 Feb 2021